HER2 e carcinoma gastrico

Allgayer H et al. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with
the expression of tumor-associated protease systems. J Clin Oncol. 2000;18(11):2201-9.
American Joint Committee on Cancer 2010. AJCC Cancer TNM Staging Manual, /a edizione, gennaio 2010. Disponibili su Associazione Italiana Registri Tumori, 2010 Bang YJ et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol 2009; 27:Abstract 4556. Bang YJ et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial; Lancet 2010;376:687-697. Blot W et al, Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA. 1991 Mar 13;265(10):1287-9. Coussens L et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985:1132-1139. Cortes-Funes H, et al.: Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification. 2007 ASCO Annual Meeting Proceedings. J Clin Oncol 2007, 25(18):s4613. Cunningham D, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358:36–46. Dank M, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19:1450–1457). Dawood S. et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28: 92-98. Devesa SS et al, Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998 Nov 15;83(10):2049-53. Di Fiore PP et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells; Science. 1987:178-182. Egamberdiev DM et al: Our experience in the use of trastuzumab in patients with advanced stomach Ferlay J et al, Estimates of the cancer incidence and mortality in Europe in 2006, Annals of Oncology 18: 581–592, 2007 Fujimoto-Ouchi K et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemother Pharmacol. 2007;59:795–805. Gravalos C & Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 2008;19:1523-1529. Hendriks BS et al. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res. 2003. 63:1130-7. Hofmann M et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 2008;52(7):797-805. Hynes NE, Stern DF. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta. 1994;1198:165-84. Kang Y.K, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009; 20:666–673. Kim SY et al, Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int J Oncol. 2008 Jan;32(1):89-95 Lordick et al. HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer. Eur J Cancer 2007;5(4):271. (Abstr 3541). Meza-Junco J et al, Critical appraisal of trastuzumab in treatment of advanced stomach cancer, Meza-Junco J, Caancer Manag Research 2011; 3:57-64 Mitzutani t et al, Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer. Cancer. 1993 Oct 1;72(7):2083-8. Murad AM et al. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72:37–41. Okines A et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v50-4. Nicholas, G. et al. Early results of a trial of trastuzumab, cisplatin, and docetaxel (TCD) for the treatment of metastatic gastric cancer overexpressing HER-2 [abstract]. Ann. Oncol. 17 (Suppl. 9), a1105P (2006). Park DI, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51:1371–1379. doi: 10.1007/s10620-005-9057-1. Parkin DM et al. Global cancer statistics, 2002; CA Cancer J Clin. 2005;55(2):74-108. Pera M et al, Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993 Feb;104(2):510-3. Satoh T, et al.: Quality of life results from a phase III trial of trastuzumab plus chemotherapy in first-line HER2-positive advanced gastric and GE junction cancer. In 2010 Gastrointestinal Cancers Symposium; Jan 22—24, 2010; Orlando, FL, USA; abstr 7. Semba K et al. A v-erbB related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth-receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci U S A. 1986;82(19):6497–501. Tanner M et al, Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005 Feb;16(2):273-8. Uchino S et al, Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients. Cancer. 1993 Dec 1;72(11):3179-84. Van Cutsem E et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group J Clin Oncol 2006;24:4991–7. Van Cutsem E, et al. Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) J Clin Oncol 2009; 27(18S):Abstract 4509. Vanhoefer U et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J Clin Oncol 2000;18:2648–57. Yang-Feng TL et al. The terminal deoxynucleotidyltransferase gene is located on human chromosome 10 (10q23----q24) and on mouse chromosome 19. Cytogenetics and Cell Genetics, 1986; 43(3-4), 121-126. Yonemura t et al, Expression of c-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for c-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma. Cancer. 1991 Jun 1;67(11):2914-8. Zhang XL, et al . Comparative study on overexpression of her2/neu and her3 in gastric cancer. World J Surg. 2009;33:2112–2118

Source: http://effetti.ecmcampus.it/ef09/upload/all/Modulo01_10.pdf


Men’s body contouring after massive weight loss What is it? Massive weight loss is generally described as being in the order of more than 50 kilograms. Such dramatic weight reduction is usually as a result of modern weight loss surgery, such as the insertion of lap bands. However, some people have managed weight reductions of this size on their own. Unfortunately, in obese people, the s


Peter H Andersen Department of Dermatology Marselisborg Hospital P.P Orumsgade 11 DK-8000 Ärhus C. Title: Treatment of recurrent herpes labialis (cold sores) using trans-cutaneous electrical nerve stimulation Purpose: To investigate if recurrent attacks of herpes labialis may be prevented or the severity diminished using trans-cutanneous electrical nerve stimulation (TCNS)

Copyright © 2010 Medicament Inoculation Pdf